Emerging treatments
Complement activation inhibitors
A number of biological agents that inhibit various stages of complement activation are being evaluated in patients with Guillain-Barre syndrome (GBS).[184] Eculizumab, a humanised monoclonal antibody that specifically binds to complement component 5, did not significantly improve motor function recovery in small phase 2 and 3 randomised clinical trials of patients with severe GBS.[185][186]
Other therapies
Small controlled trials of interferon beta-1a, brain-derived neurotrophic factor, and cerebrospinal fluid filtration failed to demonstrate significant benefit in patients with acute GBS.[187]
[ 
]
One Chinese herbal product, tripterygium polyglycoside, hastened recovery compared with corticosteroids; however, given that corticosteroids are not usually beneficial in GBS, the significance of this finding is unclear.[187] Imlifidase, a cysteine protease derived from the IgG‑degrading enzyme of Streptococcus pyogenes, is being investigated for GBS.[188][189]
Use of this content is subject to our disclaimer